The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Bipolar disorder (BD) is a mood disorder with subtypes characterized by episodes of mania, hypomania, and/or depression. BD is associated with substantial economic burden, and the bipolar I disorder (BD-I) subtype is associated with high medical costs. This review further evaluated the economic burden of BD and BD-I in the United States (US), describing health-care resource utilization (HCRU) and sources of direct medical and indirect costs. Data were obtained from systematic searches of MEDLINE ® , EMBASE ® , and National Health Service Economic Evaluation Database. Citations were screened to identify primary research studies (published 2008– 2018) on the economic burden of BD/BD-I or its treatment in real-world settings. Reported costs were converted to 2018 US dollars. Of identified abstracts (N=4111), 56 studies were included. The estimated total annual national economic burden of BD/BD-I was more than $195 billion, with approximately 25% attributed to direct medical costs. Individuals with BD/BD-I used health-care services more frequently and had higher direct medical costs than matched individuals without the disease. Drivers of higher direct costs included frequent psychiatric interventions, presence of comorbid medical/psychiatric conditions, and both suboptimal medication adherence and clinical management. Indirect costs (eg, unemployment, lost work productivity for patients/caregivers) accounted for 72– 80% of the national economic burden of BD/BD-I. Different definitions for study populations and cost categories limited comparisons of economic outcomes. This review builds on existing literature describing the economic burden of BD and confirmed cost drivers of BD/BD-I. Improved clinical management of BD/BD-I and associated comorbidities, together with better medication adherence, may reduce health-care costs and improve patient outcomes. Keywords: cost of illness, health care costs, indirect costs, mania, mood disorder, resource utilization
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Estimating the true global burden of mental illness
Vigo, D., Thornicroft, G., & Atun, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00505-2 · Cited by 2,494
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Vieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
Research works printed but not linked: 7
- Rhee, 2020, Am J Psychiatry, appiajp202019091000
- Baldessarini, 2008, Psychiatr Serv, 59, 1175, 10.1176/ps.2008.59.10.1175 · DOI · Paper page
- Pelletier, 2013, Am J Pharm Benefits, 5, e73
- Chatterton, 2008, P T, 33, 15
- Wright, 2016, J Manag Care Spec Pharm, 22, 1330
- Stensland, 2010, J Ment Health Policy Econ, 13, 87
- Seabury, 2014, Am J Manag Care, 20, e52
Cited by
Singh, B., Swartz, H. A., Barboza, A. B. C., Schaffer, A., Kato, T., Dols, A., Sperry, S. H., Vassilev, A. B., Burdick, K. E., & Frye, M. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01140-7 · Cited by 133
Yildiz, A., Siafis, S., Mavridis, D., Vieta, E., & Leucht, S. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00199-2 · Cited by 104
A Public Health Perspective of Post-Traumatic Stress Disorder
Jowf, G. I. A., Ahmed, Z. T., An, N., Reijnders, R. A., Ambrosino, E., Rutten, B. P. F., de Nijs, L., & Eijssen, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116474 · Cited by 112
“Nearly all previous researchers found that indirect cost weighs similar or more in magnitude in the overall economic burden than direct costs [31,33,34].”
BackgroundThe burden of anxiety among a nationally representative US adult population
Kavelaars, R., Ward, H. E., Mackie, D. S., Modi, K., & Mohandas, A. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.069 · Cited by 64
Rathour, D., Shah, S., Khan, S., Singh, P. K., Srivastava, S., Singh, S. B., & Khatri, D. K. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114081 · Cited by 61
McGhee, C. E., Yang, Z., Guo, W., Wu, Y., Lyu, M., DeLong, C. J., Hong, S., Ma, Y., McInnis, M. G., O'Shea, K. S., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00843 · Cited by 58
The costs of bipolar disorder in the United Kingdom
Simon, J., Pari, A. A. A., Wolstenholme, J. L., Berger, M., Goodwin, G. M., & Geddes, J. R. (2021) · Brain and Behavior · doi:10.1002/brb3.2351 · Cited by 44
The economic and humanistic burden of bipolar disorder in adults in the United States
Dembek, C., Mackie, D. S., Modi, K., Zhu, Y., Niu, X., & Grinnell, T. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-023-00440-7 · Cited by 44
“Abbreviations BMI Body mass index CCI Charlson Comorbidity Index CI Confidence intervals EQ-5D EuroQol 5-Dimension Health Questionnaire ER Emergency room GAD-7 General Anxiety Disorder 7-item scale GLM Generalized linear model HCRU Healthcare resource utilization HRQoL Health-related quality of life ICH International…”
BackgroundInfluentialMicale, V., Bartolomeo, M. D., Martino, S. D., Štark, T., Dell’Osso, B. M., Drago, F., & D’Addario, C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108279 · Cited by 41
Advances and Applications of Brain Organoids
Li, Y., Zeng, P.-M., Wu, J., & Luo, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01065-2 · Cited by 40
“Bipolar patients experience recurrent episodes of depression and mania that affect perception, emotion, thought, and social behavior [148].”
BackgroundSulfur‐Containing Foldamer‐Based Artificial Lithium Channels
Shen, J., Deepa, R., Li, Z.-Y., Oh, H., Behera, H., Joshi, H. N., Kumar, M., Aksimentiev, A., & Zeng, H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202305623 · Cited by 36
Prenatal and perinatal risk factors for bipolar disorder: A systematic review and meta-analysis
Shintani, A. O., Rabelo‐da‐Ponte, F. D., Marchionatti, L. E., Watts, D., de Souza, F. F., Machado, C. D. S., Pulice, R. F., Signori, G. M., Luzini, R. R., Kauer‐Sant’Anna, M., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104960 · Cited by 30
Amanollahi, M., Jameie, M., Looha, M. A., Basti, F. A., Cattarinussi, G., Moghaddam, H. S., Camillo, F. D., Akhondzadeh, S., Pigoni, A., Sambataro, F., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.061 · Cited by 27
Liu, Y. S., Chokka, S., Cao, B., & Chokka, P. R. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100215 · Cited by 30
Siegel, J. E., Sharp, S. J., Ulack, C., Chiang, K. S., di Scalea, T. L., O’Hara, S., Carberry, K. E., Strakowski, S. M., Suarez, J., Teisberg, E. O., et al. (2023) · International Journal of Bipolar Disorders · doi:10.1186/s40345-023-00293-9 · Cited by 27
Li, Y., Jie, T., Xiao, Y., Ren, T., Yang, J., Lin, Y., & Zheng, C. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00783 · Cited by 24
Wittenborn, A. K., Woods, S., Priest, J. B., Morgan, P. C., Tseng, C., Huerta, P. L., & Edwards, C. (2021) · Journal of Marital and Family Therapy · doi:10.1111/jmft.12569 · Cited by 25
Ohi, K., Nishizawa, D., Sugiyama, S., Takai, K., Kuramitsu, A., Hasegawa, J., Soda, M., Kitaichi, K., Hashimoto, R., Ikeda, K., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab014 · Cited by 23
Hatano, M., Nakajima, W., Tani, H., Uchida, H., Miyazaki, T., Arisawa, T., Takada, Y., Tsugawa, S., Sano, A., Nakano, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02785-1 · Cited by 22
“Psychiatric disorders such as schizophrenia, bipolar disorder, depression, and autism spectrum disorder (ASD) are common serious diseases which impair social functioning and lower quality of life [1] on an individual level as well as a signi fi cant economic loss on a societal level [2, 3].”
Doane, M. J., Raymond, K., Saucier, C. D., Bessonova, L., O’Sullivan, A. K., White, M. K., Foster, A. M., LaGasse, K., Carpenter-Conlin, J., Sajatovic, M., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04746-4 · Cited by 22
“As a consequence, people living with SZ or BD-I have increased health care resource use and associated medical costs [5, 6].”
BackgroundSelf-citationEarly use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus
Vieta, E., Tohen, M. F., McIntosh, D., Kessing, L. V., Sajatovic, M., & McIntyre, R. S. (2024) · Bipolar Disorders · doi:10.1111/bdi.13498 · Cited by 21
“…direct and indirect costs of bipolar disorder, including BP-I, in the United States alone are estimated to be more than $195 billion annually, 25 yet the greatest societal cost associated with bipolar disorder relates to significant loss of life due to suicide, 26 followed by cardiovascular…”
Self-citationTegtmeyer, M., Liyanage, D., Han, Y., Hebert, K. B., Pei, R., Way, G. P., Ryder, P. V., Hawes, D., Tromans‐Coia, C., Cimini, B. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61547-x · Cited by 19
“…suffering from mental illness face debilitating symptoms, including dramatic mood swings, persistent hallucinations, and increased risk of substance abuse and suicidality, contributing to severe personal and societal consequences such as unemployment, homelessness, and incarceration 1,2 .”
Brozena, J., Blair, J., Richardson, T. H., Matthews, M. L., Mukherjee, D., Saunders, E. F. H., & Abdullah, S. (2024) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642645 · Cited by 21
“A 2015 analysis estimated its total costs in the US economy to be $202.1 billion, amounting to $81,559 per individual [6, 12].”
BackgroundMethodInfluentialKuhney, F. S., Miklowitz, D. J., Schiffman, J. E., & Mittal, V. A. (2023) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/23727322221128251 · Cited by 16
“Psychiatric relapse places a significant burden on public health care systems, with annual costs estimated as high as $195 billion dollars (Bessonova et al., 2020).”
BackgroundNarrative-based psychotherapies for mood disorders: A scoping review of the literature
Hawke, L. D., Nguyen, A. T. P., Rodak, T., Yanos, P. T., & Castle, D. J. (2023) · SSM - Mental Health · doi:10.1016/j.ssmmh.2023.100224 · Cited by 14
RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers
Pisanu, C., & Squassina, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210067 · Cited by 14
“Nonetheless, it has relevant prognostic and therapeutic implications, since the misdiagnosis or mistreatment of BD has been associated with a more severe disease course and a higher number of hospitalizations and suicide attempts [88], as well as increased costs [89].”
BackgroundIelmini, M., Caselli, I., Critelli, F., Mattia, M., Bellini, A., & Callegari, C. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114482 · Cited by 14
O’Donnell, L. A., Helmuth, M. E., Williams, S., McInnis, M. G., & Ryan, K. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.095 · Cited by 14
Doane, M. J., Ogden, K., Bessonova, L., O’Sullivan, A. K., & Tohen, M. F. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s280051 · Cited by 14
“BD-I is associated with considerable disease and economic burden, as well as reduced quality of life, relative to other subtypes of bipolar disorder.(2,3,12,13) To better understand real-world use of SGAs to treat patients with mania or predominately manic symptoms in the US, this review was conducted to: 1) character…”
BackgroundSelf-citationForma, F. M., Chiu, K., Shafrin, J. T., Boskovic, D. H., & Veeranki, S. P. (2022) · Digital Health · doi:10.1177/20552076221084472 · Cited by 14
“S is $195 billion, $325 billion and $155 billion, respectively9–11 with 70–80% of burden attributed to indirect costs that include productivity loss or unemployment by patients or caregivers, missed time at school, medication adherence issues and caregiving support.(9,12,13) Patients with SMI face several mental, beha…”
BackgroundIturralde, E., Fazzolari, L., Shia, M., Slama, N. E., Leang, J., Awsare, S. V., & Nguyen, L. T. (2022) · NEJM Catalyst · doi:10.1056/cat.21.0417 · Cited by 12
The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis
Barer, Y., Ribalov, R., Yaari, A., Maor, R., Arow, Q., LOGAN, J. R., Chodick, G., Arkadir, D., & Eitan, R. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001597 · Cited by 13
Palacios-Ariza, M. A., Morales-Mendoza, E., Murcia, J., Arias-Duarte, R., Lara-Castellanos, G., Cely-Jiménez, A., Acuña, J. C. R., Araúzo-Bravo, M. J., & McDouall, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1266548 · Cited by 13
“Patient admissions are preventable events with a considerable impact on healthcare costs and a key quality metric for health systems around the world (12–14).”
BackgroundFelice, G. D., Luciano, M., Boiano, A., Colangelo, G., Catapano, P., Rocca, B. D., Lapadula, M. V., Piegari, E., Toni, C., & Fiorillo, A. (2023) · Brain Sciences · doi:10.3390/brainsci13081221 · Cited by 14
“Moreover, BD is associated with a significant economic burden [10], with an estimated total annual national economic expenditure of more than USD 195 billion in the US alone, with approximately 25% attributed to direct medical costs [10] and the remaining to loss of productivity.”
BackgroundMcIntyre, R. S., Bloudek, L. M., Timmons, J. Y., Gillard, P. J., & Harrington, A. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2177413 · Cited by 11
Zarezadeh, F., Arbabi, M., Shamabadi, A., Naderi, S., Hasanzadeh, A., Ostadpour, M., Samsami, F. –. S., & Akhondzadeh, S. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000383 · Cited by 11
“The economic burden of the disorder in the USA is estimated at $200 billion per year (Bessonova et al., 2020).”
BackgroundEseaton, P. O., Oladunjoye, A. F., Anugwom, G., Onyeaka, H., Edigin, E., & Osiezagha, K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.086 · Cited by 11
Vgontzas, A. N., Paschalidou, A., Simos, P. G., Anastasaki, M., Zografaki, A., Volikos, E., Koutra, K., & Basta, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115676 · Cited by 10
Teigland, C. L., Mohammadi, I., Agatep, B. C., Boskovic, D. H., & Sajatovic, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.1.72 · Cited by 10
Woo, Y. S., Jeong, J., Kang, H., Lee, K., Shim, S.-H., Kwon, Y., Lee, S.-Y., Jang, S.-H., Park, Y., Jon, D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.257 · Cited by 10
Identification of depression predictors from standard health surveys using machine learning
Jamali, A. A., Berger, C., & Spiteri, R. J. (2024) · Current Research in Behavioral Sciences · doi:10.1016/j.crbeha.2024.100157 · Cited by 10
Predicting cognitive functioning in mood disorders through smartphone typing dynamics.
Ning, E., Estabrook, R., Tulabandhula, T., Zulueta, J., Ross, M. K., Kabir, S., Hussain, F., Langenecker, S. A., Ajilore, O., Leow, A., et al. (2025) · Journal of Psychopathology and Clinical Science · doi:10.1037/abn0001052 · Cited by 10
Sulfur‐Containing Foldamer‐Based Artificial Lithium Channels
Shen, J., Deepa, R., Li, Z.-Y., Oh, H., Behera, H., Joshi, H. N., Kumar, M., Aksimentiev, A., & Zeng, H. (2023) · Angewandte Chemie · doi:10.1002/ange.202305623 · Cited by 8
Li, N. C., Alcusky, M. J., Masters, G. A., & Ash, A. S. (2021) · Medical Care · doi:10.1097/mlr.0000000000001670 · Cited by 8
Benáček, J., Martin-Key, N. A., Spadaro, B., Tomasik, J., & Bahn, S. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00261-9 · Cited by 8
Sperry, S. H., Douglas, K. M., Dean, O. M., Fries, G. R., Gomes, F. A., Hosang, G. M., Morton, E. E., Sandorffy, B. L., Rheenen, T. E. V., Xu, N., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13365 · Cited by 8
Hogg, B., Raduà, J., Gardoki-Souto, I., Fontana-McNally, M., Lupo, W., Reinares, M., Jiménez, E., Madre, M., Blanco, L., Cortizo, R., et al. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2023.11.005 · Cited by 7
The economic burden of bipolar disorder: a case study in Southern Iran
Shaker, Z., Goudarzi, Z., Ravangard, R., Shaker, Z., Hedayati, A., & Keshavarz, K. (2024) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-024-00560-1 · Cited by 7
“…Besonova et al. (2020) on the economic burden of BC, it was concluded that the largest share of DMC was related to frequent psychiatric interventions [37], the reason for which might be the difference in the prices of psychiatric services in America and the difference in their treatment guidelines.”
BackgroundHaddad, H. W., Boardman, E., Williams, B., Mouhaffel, R., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.34224 · Cited by 7
Yi, W., Wu, H., Li, R., Li, H., Song, Z., She, S., & Zheng, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.984829 · Cited by 7
“The inclusion criteria were as follows: (1) inpatients diagnosed with BD; (2) aged ≥18 years; (3) admitted to our hospital between January 1, 2019, and December 31, 2019; and (4) had a record of BMI at admission to the hospital.”
BackgroundInfluentialdbBIP: a comprehensive bipolar disorder database for genetic research
Li, X., Ma, S., Yan, W., Wu, Y. Q., Kong, H., Zhang, M., Luo, X., & Xia, J. (2022) · Database · doi:10.1093/database/baac049 · Cited by 7
“For example, in the USA alone, the national economic burden of BIP exceeded 195 billion dollars in 2020, with 25% directly attributed to healthcare costs (7).”
BackgroundHu, Z., Han, Y., Hu, M., Zhang, H., Yuan, X., & Yu, H. (2024) · Acta Psychologica · doi:10.1016/j.actpsy.2024.104137 · Cited by 8
A Retrospective Cross-Sectional Analysis of the Humanistic and Economic Burden of Bipolar I Disorder
Culpepper, L., Martin, A., Harrington, A., Wade, S. W., & Parikh, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.08.003 · Cited by 6
Trauma-Informed Yoga: A Scoping Review
Klukan, K., & Lunsford, D. (2023) · Occupational Therapy in Mental Health · doi:10.1080/0164212x.2023.2276148 · Cited by 6
“For example, a systematic review by Bessonova et al. (2020) estimated in 2018, the United States spent more than $195 billion on bipolar disorder related issues, secondary to indirect costs, such as loss of productivity to be almost 80% of the economic distress.”
Laliberté, F., Zanardo, E., MacKnight, S. D., Urosevic, A., Wade, S. W., & Parikh, M. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.2.118 · Cited by 6
McLean, M., Henderson, T. A., Pavel, D. G., & Cohen, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.829561 · Cited by 6
Place of care and costs associated with acute episodes and remission in bipolar I disorder
McIntyre, R. S., Higa, S., Doan, Q. V., Amari, D. T., Oliveri, D., Gillard, P. J., & Harrington, A. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2120264 · Cited by 6
Prevalence and Risk Factors of Comorbid Obesity in Chinese Patients with Bipolar Disorder
Wu, Q., Zhang, X., Liu, Y., & Wang, Y. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s404127 · Cited by 6
“In the United States, the annual national economic burden of BD and its medical comorbidities is estimated at more than $195 billion.(3) The studies in China have found that Chinese men and women with BD lose 6.”
BackgroundThe conundrum of antidepressant use in bipolar disorder
Scaini, G., & Quevedo, J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01930-y · Cited by 6
“Of all mood disorders, BD has the highest likelihood (89%) of severe impairment, an estimated suicide risk of 17%, and is the sixthleading cause of worldwide disability [2].”
BackgroundDoane, M. J., Thompson, J. E., Jauregui, A., Gasper, S., & Csoboth, C. T. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s411928 · Cited by 5
“Cardiovascular disease is a leading cause of morbidity and mortality in people with BD-I, and the development of obesity-related cardiometabolic comorbidities that may emerge secondary to weight gain from antipsychotic and mood stabilizer treatments significantly increases HCRU and direct medical costs.(13,18) Antipsy…”
BackgroundSelf-citationMiranda-Mendizábal, A., Vetter, D., Zambrano, J., Zarp, J., Chavarria, V., Giménez‐Palomo, A., González‐Campos, M., Valentí, M., Baldinazzo, L. W., Siddi, S., et al. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-024-00544-8 · Cited by 7
Isolating the Genetic Component of Mania in Bipolar Disorder
Merola, G. P., Zvrskovec, J., Wang, R., Li, Y. K., Castellini, G., Ricca, V., Coleman, J., Vassos, E., & Breen, G. D. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.008 · Cited by 5
Trivedi, C. G., Vadukapuram, R., Chaudhari, G., Ashraf, S., Tazin, F., Mansuri, Z., & Jain, S. B. (2022) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001506 · Cited by 5
Challenges of lithium prescription in bipolar disorders in Nigeria
Adiukwu, F. N., Salihu, M. O., Hayatudeen, N., Kareem, Y. A., Adegoke, B. O., Charles-Ugwuagbo, I. C., Uwah, E. E., Adesina, I. O., Ibrahim, A. M., & Fugu, M. A. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06736-0 · Cited by 5
“Economically, the annual burden of BD is staggering, amounting to 195 billion US dollars [7].”
Ko, H., Park, D., Shin, J. H., Yu, R., Ryu, V., & Lee, W. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.951043 · Cited by 5
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2022) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v33i158.319 · Cited by 5
Lewis, P., Gottlieb, J. F., Morfeld, P., Hellmich, M., & Erren, T. C. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115878 · Cited by 5
Huang, H., Schmerold, L. M., Dembek, C., Fan, Q. W., Dieyi, C., Williams, G. R., & Loebel, A. D. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1890428 · Cited by 6
Niu, X., Dembek, C., Fan, Q. W., Mao, Y., Divino, V. M., Burch, S. P., & Tocco, M. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2030147 · Cited by 5
Gu, J., Qian, K., Wu, G., & Xu, H. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673355842250213103507 · Cited by 5
Bailey, B. C., Tabone, J. K., Early, T. J., Wen, S., Leber, A., & Swartz, H. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120121 · Cited by 5
Gardea‐Resendez, M., Pazdernik, V., Jezzini‐Martinez, S., Coombes, B. J., Beaupre, L. M., Ho, A. M., Sánchez-Ruiz, J. A., Miola, A., Ercis, M., Andreazza, A. C., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120632 · Cited by 6
Yalın, N., Yildiz, A., Siafis, S., Vieta, E., & Leucht, S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112818 · Cited by 6
Miola, A., Prisco, M. D., Lussignoli, M., Meda, N., Dughiero, E., Costa, R., Núñez, N. A., Fornaro, M., Veldić, M., Frye, M. A., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1435199 · Cited by 5
Malau, I. A., Chiu, Y., Chang, H.-C., Yang, Y., Chang, J. P., Correll, C. U., Vieta, E., & Su, K. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70013 · Cited by 5
“Moreover, patients with BD exhibit shortened life expectancy (LE) [12] and increased years- of- potential- life-lost [13], increased hospital admissions compared to other mental disorders [14, 15], and increased medical expenses [16, 17].”
Kheloussi, S. S., Oberlin, J., Trauger, M., & Testa, N. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.10.1130 · Cited by 4
Khandker, R. K., Chekani, F., Limone, B. L., & Riehle, E. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2228165 · Cited by 4
“Non-adherence to therapy among bipolar disorder patients has been associated with relapses and higher healthcare costs 5 .”
BackgroundDiagnosis, Clinical Features, Differential Diagnosis, and Psychiatric Comorbidities
Vasconcelos-Moreno, M. P., Pinto, J. V., Hasse-Sousa, M., Melo, I. M. D. S., Saviatto, N. G., Lucas, P. K., Baldez, D. P., Passos, I. C., & Kapczinski, F. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_6 · Cited by 4
Niu, X., Dennen, S., Dembek, C., Laubmeier, K. K., Liu, Y., Veeranki, S. P., Tocco, M., & Williams, G. R. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100629 · Cited by 4
Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2419721 · Cited by 3
Cutler, A. J., Panchmatia, H. R., Hughes, A. G., Webb, N. S., Doane, M. J., & Jain, R. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03211-w · Cited by 3
“Serious mental health conditions, including schizophrenia (SZ) and bipolar I disorder (BD-I), are associated with considerable financial cost to the affected individuals, their families, and the healthcare system [1–5].”
Self-citationHerpertz, J., Schönbeck, J., Opel, N., Stern, A. D., Torous, J. B., & Schwarz, J. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00377-0 · Cited by 3
“Given that SMI accounts for a substantial share of overall mental healthcare costs [ 24, 25 ], developing digital treatment options for SMI that could be deployed in a resource-efficient manner is par - ticularly important.”
Özer, G., Işık, İ., & Escartín, J. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21020137 · Cited by 4
Simutkin, G. G. (2024) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2024-902 · Cited by 3
Physical fitness in patients with bipolar disorder compared with a population‐based sample
Kheradmand, A., AbediYekta, A. H., Safarzadeh, H., & Ganjalikhani, M. (2022) · Health Science Reports · doi:10.1002/hsr2.507 · Cited by 3
“5% to 1% of the general population, which is accompanied by another psychiatric disorder.(1,2) The sex ratio is 1:1, which increases with aging.”
BackgroundExercise and Psychotherapy in the Treatment of Bipolar Disorder
Zhou, M., Hong, X., Qin, J., & Song, X. (2023) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-6684-6040-5.ch010 · Cited by 3
Acquiring Resourcefulness Skills: Formal Versus Informal Training
Zauszniewski, J. A., Burant, C. J., Juratovac, E., Jeanblanc, A., Sweetko, J. S., Larsen, C., Almutairi, R. R., She, H. Y., DiFranco, E., Colón-Zimmermann, K., et al. (2024) · Western Journal of Nursing Research · doi:10.1177/01939459241296613 · Cited by 4
Identifying and targeting abnormal mitochondrial localization associated with psychosisPreprint
Haghighi, M., McPhie, D. L., Rohban, M. H., Weisbart, E., Logan, D. J., Karhohs, K. W., Babb, S. M., Ewald, J., Haslum, J. F., Ravichandran, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.676630 · Cited by 3
“These conditions include schizophrenia, schizoaffective disorder and bipolar disorder, which collectively have an enormous economic, social, and emotional impact (Bessonova et al. 2020; Kadakia et al. 2022; Lin et al. 2022).”
Mammadov, B. B., Yıldızhan, E., & Tomruk, N. B. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104625 · Cited by 2
Womer, F. Y., Xiao, Y., Ngo, V., Zheng, J., & Wang, F. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0045 · Cited by 2
“[2-8] Further treatment innovations are needed to improve the lives of individuals with psychiatric disorders such as SCZ, BD, and MDD and their families.”
Insights, challenges and new frontiers for cognitive function in bipolar disorder
Miskowiak, K. W., Kjærstad, H. L., Vieta, E., & Yatham, L. N. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00615-7 · Cited by 4
Bipolar spectrum disorders among American registered nurses: a narrative literature review
Armijo, J. (2023) · Discover Psychology · doi:10.1007/s44202-023-00072-8 · Cited by 2
“In 2013, the United States Bureau of Labor Statistics found that nurses comprise 4% of the total workforce in the United States [16].”
BackgroundInfluentialBoere, E., van der Wee, N. J. A., van Hemert, B., WEBB, A. G., & de Leeuw, M. (2025) · Psychoradiology · doi:10.1093/psyrad/kkaf003 · Cited by 2
“Around 50% of the time subjects with BD experience depressive or manic symptoms (Kupka et al. , 2007 ), resulting in severely impair ed health-r elated quality of life and high societal costs (Bessonova et al. , 2020 ).”
Niu, X., Veeranki, P., Dennen, S., Dembek, C., Laubmeier, K. K., Liu, Y., Williams, G. R., & Loebel, A. D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1897557 · Cited by 3
Yokotani, K., Takano, M., & Abe, N. (2023) · IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining (ASONAM) · doi:10.1145/3625007.3627319 · Cited by 2
“People with BD are prone to high medical costs due to the need for high-frequency medical services for a variety of problem behaviors, costing $48 billion annually in the U.S. alone [2].”
BackgroundCase identification and healthcare utilization in the years prior to a first mania diagnosis
Benson, N. M., Yang, Z., Fung, V., Smoller, J. W., Öngür, D., & Hsu, J. T.-A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.117 · Cited by 1
Diaby, V., Pandey, S., Sanogo, V., Almutairi, R., Kanoria, Y., & Nag, S. S. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.1.60 · Cited by 1
Ralph, L. N., & Kohler, C. G. (2025) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903251354945 · Cited by 1
“While prevalence rates for both major depression and bipolar disorder are much higher than schizophrenia, they are associated with similar economic burdens (Bessonova et al., 2020; Greenberg et al., 2023).”
Gardea‐Resendez, M., Salgado, M. F., Romo‐Nava, F., Prieto, M. L., Bond, D. J., Özerdem, A., Betcher, H. K., Moore, K. M., Solares‐Bravo, M., Ercis, M., et al. (2025) · Bipolar Disorders · doi:10.1111/bdi.70062 · Cited by 1
“In the absence of studies focused on BD and SDoH, it is reasonable to hypothesize that the high rates of unemployment and socioeconomic burden in BD might be indicative of broader environmental struggles [5, 6, 10].”
The path towards stability: treatment with medicines in bipolar disorder
Novais, A. F. S. A., Filardi, A. F. R., & de Oliveira, D. R. (2025) · Estudos de Psicologia (Campinas) · doi:10.1590/1982-0275202542e2510898 · Cited by 1
Metadata
- Authors
- Bessonova, L., Ogden, K., Doane, M. J., O'Sullivan, A. K., & Tohen, M.
- Affiliations
- Alkermes (United States) (US)
- Worldwide Clinical Trials (United States) (US)
- University of New Mexico (US)
- Corresponding author
- Bessonova, Leona
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2020-09
- Volume
- Volume 12
- Pages
- 481-497
- ISSN
- 1178-6981 (ISSN-L)
- PMC
- PMC7489939
- OpenAlex
- W3083267042
- Semantic Scholar
- 4b10052566feb7dd1f10943dfd9f816c3f7583ab
- Cited by
- 147
- References
- 78
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 29 · 2023: 29 · 2022: 28 · 2021: 12 · 2020: 1
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- bipolar disorder, bipolar I disorder, economic burden, healthcare resource utilization, direct medical costs, indirect costs, productivity loss, medication adherence, comorbidities, mania, mood disorders, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.